Patents Assigned to Kinki University
  • Patent number: 11479537
    Abstract: A new analgesic has been developed for T-type calcium channels as therapeutic targets. The present invention provides a T-type calcium channel inhibitor which is a compound represented by formula (1): wherein each of R1 and R2 independently represents —H or —OH; R3 represents —OH; R4 represents —OH or —H; R5 represents a straight or branched alkyl or cycloalkyl-alkyl group having one to ten carbon atoms or a straight or branched alkenyl or cycloalkyl-alkenyl group having two to ten carbon atoms, or a pharmaceutically acceptable salt or solvate thereof. The present invention also provides this T-type calcium channel inhibitor, a medicament containing the T-type calcium channel inhibitor, and a therapeutic or prophylactic agent for a disease having an effective T-type calcium channel inhibitory action.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: October 25, 2022
    Assignees: KINKI UNIVERSITY, NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA, FUSO PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: Atsufumi Kawabata, Fumiko Sekiguchi, Maho Tsubota, Naoki Toyooka, Hiroyuki Nishikawa
  • Publication number: 20220323385
    Abstract: An aortic aneurysm has few noticeable symptoms and is at high risk for rupture without a sign of abnormality. Further, if it ruptures, it causes a shock state due to massive blood loss and results in a very low survival rate. Thus, when the aortic aneurysm is found by physical examination or the like, a surgery with a stent graft or the like needs to be performed according to the state of its progression. A pharmaceutical composition for preventing an aortic aneurysm including a medium chain fatty acid as a main component has an effect of inhibiting the occurrence and progression of the aortic aneurysm. Thus, when the aortic aneurysm is found, the composition through continuous intake can exhibit effects including inhibition of the progression of the aortic aneurysm and improvement in the vital prognosis.
    Type: Application
    Filed: June 19, 2020
    Publication date: October 13, 2022
    Applicants: KINKI UNIVERSITY, YASHIRO CO., LTD., OSAKA UNIVERSITY
    Inventors: Nobuhiro ZAIMA, Hirona KUGO, Motohiro KITANO, Yoshinori HIROTA, Ken-ichi HIRANO
  • Patent number: 11446608
    Abstract: The present invention relates to a method for reducing the HTO concentration in a tritium-containing aqueous solution. The present invention includes bringing water vapor or the like of a tritium-containing aqueous solution into contact with a porous material having pores in a pore diameter range of 500 ? or less, selectively occluding the HTO in the tritium-containing aqueous solution in the porous material, and obtaining a tritium-containing aqueous solution in which the HTO concentration thereof is reduced. The present invention relates to a device used for reducing the HTO concentration in a tritium-containing aqueous solution.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: September 20, 2022
    Assignees: KINKI UNIVERSITY, A ATOM TECHNOL KINDAI, TOYO ALUMINIUM KABUSHIKI KAISHA
    Inventors: Tatsuhiko Ihara, Hirokuni Yamanishi, Hiroshi Noma, Toshifumi Taira, Takashi Hoshiya, Kazuya Fujimoto
  • Patent number: 11432552
    Abstract: To improve the fact that the main components of conventional deodorizing and antimicrobial agents are existing components, the effect and efficacy of which are known to some extent, and do not generate an effect better than predicted. The deodorizing and antimicrobial agent of the present invention has a loquat seed extract including non-volatile fatty acids and at least benzaldehyde and benzoic acid as a main raw material.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: September 6, 2022
    Assignees: RILIS CO., LTD., KINKI UNIVERSITY
    Inventors: Atsushi Henmi, Masato Nomura
  • Patent number: 11420944
    Abstract: A compound represented by the following General Formula (I), a tautomer or a stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, is used as a voltage-dependent T-type calcium channel blocker: wherein A represents a 5-membered heteroaryl group or a fused ring of a 5-membered or 6-membered heterocyclic ring with a benzene ring or a pyridine ring, each of which may have a substituent; R represents a hydrogen atom or the like; B represents CR5(Q1) or NQ2, herein Q1 represents a benzimidazole group which may have a substituent, or the like; Q2 represents an alkyl group having 1 to 8 carbon atoms which may have a substituent, a heteroaryl group which may have a substituent, or the like; R0, R1, R2, R3, R4, and R5 each represent a hydrogen atom or the like; and n and m each represent 0, 1, or 2.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: August 23, 2022
    Assignees: Nippon Chemiphar Co., Ltd., Kinki University
    Inventors: Hiroto Tanaka, Isao Ooi, Yuzo Mogi, Masaaki Hirose, Tsuyoshi Endo, Toru Ogawa, Atsufumi Kawabata
  • Publication number: 20220251489
    Abstract: An object is to provide a cell culture scaffold which makes it possible to recover a cell culture product without being destroyed after cell culturing and a method for producing a cell culture product. The cell culture scaffold according to the present invention includes a substrate having a water-repellent surface and a cell adhesion molecule formed on the water-repellent surface of the substrate. Further, the method for producing a cell culture product according to the present invention includes a step of culturing, using the cell culture scaffold, cells on the surface of the cell adhesion molecule. The cell culture scaffold according to the present invention makes it possible to recover the cells in a spheroid state without causing a damage.
    Type: Application
    Filed: July 6, 2020
    Publication date: August 11, 2022
    Applicant: KINKI UNIVERSITY
    Inventors: Masanobu KUSUNOKI, Hiroki TAKEUCHI, Hidetaka TOGO
  • Publication number: 20220226299
    Abstract: A medicament for treating or preventing pruritus is provided. For the medicament for treating or preventing pruritus, a compound having a blocking action on Cav3.2T-type calcium channels represented by General Formulas (I) to (VI), a tautomer of the compound, a stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an active ingredient.
    Type: Application
    Filed: March 26, 2020
    Publication date: July 21, 2022
    Applicants: NIPPON CHEMIPHAR CO., LTD., UTI LIMITED PARTNERSHIP, KINKI UNIVERSITY
    Inventors: Gerald W. ZAMPONI, Vinicius de Maria GADOTTI, Atsufumi KAWABATA, Toru OGAWA, Hiroto TANAKA, Isao OOI, Daisuke SAITO, Kohei HAYASHIDA, Kohei YAMAMOTO
  • Patent number: 11370761
    Abstract: A compound represented by General Formula (I), a tautomer, a stereoisomer, or a pharmaceutically acceptable salt of the compound, or a solvate thereof is used as a voltage-dependent T-type calcium channel inhibitor, in the formula, A represents a benzene ring which may have a substituent or the like; B represents a hetero-fused ring consisting of a 5- or 6-membered heteroaryl ring having one to three same or different heteroatoms selected from an oxygen atom, a sulfur atom, and a nitrogen atom, and a carbon atom, as a ring-constituting atom, and a benzene ring, or the like, and the hetero-fused ring may have a substituent, and is bonded to a cyclopropyl group via a carbon atom constituting these rings; R1 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or the like; R2 and R3 may be the same as or different from each other, and each represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or the like, or R2 and R3 together form CH2CH2 or the like; R4 represents a hydr
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: June 28, 2022
    Assignees: Nippon Chemiphar Co., Ltd., Kinki University
    Inventors: Hiroto Tanaka, Isao Ooi, Kohei Hayashida, Toru Ogawa, Atsufumi Kawabata
  • Patent number: 11371995
    Abstract: A method for selecting an individual to be a candidate for administration of an immune checkpoint inhibitor in treatment of a tumor, comprising: (1) a step of collecting a tumor tissue from the individual, (2) a step of determining the extent of B7-H3 expression in the tumor tissue collected in step (1), and (3) a step of selecting the individual as an individual to be a candidate for administration of the immune checkpoint inhibitor if the B7-H3 expression level is considered to be negative, is provided.
    Type: Grant
    Filed: December 25, 2017
    Date of Patent: June 28, 2022
    Assignees: Daiichi Sankyo Company, Limited, Kinki University
    Inventors: Kimio Yonesaka, Kazuhiko Nakagawa, Kenji Hirotani
  • Publication number: 20220135514
    Abstract: Phytol contained in watermelon sprouts is known to have a cancer cell growth inhibiting effect. However, there is a problem that an amount of phytol to be taken for exhibiting cancer cell growth inhabition is large. A cancer cell growth inhibiting composition comprising at least one of compounds having a structure represented by Formula (1), Formula (2), Formula (6), Formula (7) or Formula (8), or a pharmaceutically acceptable salt thereof as main components has a higher cancer cell growth inhibiting effect than phytol.
    Type: Application
    Filed: February 21, 2020
    Publication date: May 5, 2022
    Applicants: HAGIHARA FARM PRODUCTION INSTITUTE CO., LTD., KINKI UNIVERSITY, MIE UNIVERSITY
    Inventors: Toshiharu HASHIZUME, Takashi KITAYAMA, Gengo KASHIWAZAKI, Satoru HIRABAYASHI, Yoshimi UTAKA, Keigo TANEDA, Tomohiro ITOH
  • Publication number: 20210275616
    Abstract: No drug has been available for treating a peripheral sensory neuropathy caused as a side effect by a drug, in particular, by an anticancer drug such as oxaliplatin. A composition for ameliorating peripheral sensory neuropathy, which is characterized by including a Lentinus edodes mycelium extract, ameliorates symptoms induced by the drug such as the anticancer drug, including numbness of extremities, a pain in extremities, a reduction in deep tendon reflection, a reduction in muscle force, allodynia, hyperalgesia, impaired finger fine movement, impaired walking, stumbling, falling, impaired flexion (being difficult or impossible to sit on one's heels, sit cross-legged, sit with one's legs out to one side, sit on a chair, or the like), or paralysis of extremities.
    Type: Application
    Filed: May 24, 2021
    Publication date: September 9, 2021
    Applicants: KINKI UNIVERSITY, KOBAYASHI PHARMACEUTICAL CO., LTD.
    Inventors: Shozo NISHIDA, Masanobu TSUBAKI, Tomoya TAKEDA, Kiyotaka OKUNO, Satoshi WACHI
  • Publication number: 20210047385
    Abstract: A nerve cell culture material including LASCol has the effect of successfully maintaining survival of the nerve cell. Furthermore, a therapeutic agent for nerve damage including LASCol can allow an endogenous nerve cell to infiltrate or proliferate actively in vivo, thereby enabling neurites to extend early and bind to each other, and has an effect on nerve damage, the effect being sufficient to improve a BBB score.
    Type: Application
    Filed: January 31, 2019
    Publication date: February 18, 2021
    Applicants: KINKI UNIVERSITY, AINO UNIVERSITY, FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE
    Inventors: Koichi MORIMOTO, Saori KUNII, Kenji KANEKIYO, Norihiko NAKANO, Chizuka IDE, Kaoru OMAE
  • Publication number: 20210046214
    Abstract: A therapeutic agent for intervertebral disc degeneration that contains LASCol obtained by enzymatically cleaving a terminus of collagen.
    Type: Application
    Filed: January 31, 2019
    Publication date: February 18, 2021
    Applicants: NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY, KINKI UNIVERSITY, FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE
    Inventors: Takashi YURUBE, Yoshiki TAKEOKA, Koichi MORIMOTO, Saori KUNII, Kaoru OMAE
  • Publication number: 20210003579
    Abstract: Disclosed is a method for assisting a determination of an efficacy of an immune checkpoint inhibitor, the method comprising: measuring a free protein marker in a liquid sample collected from a subject; and determining the efficacy of the immune checkpoint inhibitor in the subject based on a result of the measurement, wherein the free protein marker is at least one selected from free Cytotoxic T lymphocyte antigen-4 (CTLA-4), free Programmed cell death-1 (PD-1) and free Programmed cell death-ligand 1 (PD-L1).
    Type: Application
    Filed: September 23, 2020
    Publication date: January 7, 2021
    Applicants: KYOTO UNIVERSITY, Kinki University, ONO PHARMACEUTICAL CO., LTD., SYSMEX CORPORATION
    Inventors: Tasuku HONJO, Kenji CHAMOTO, Hidetoshi HAYASHI, Kazuhiko NAKAGAWA, Megumi GOTO, Hitoshi UGA
  • Patent number: 10758583
    Abstract: A so-called molecular-targeted drug acting on a signal transduction pathway in a cell has been developed. However, a side effect of the molecular-targeted drug is not negligible for a patient. Thus, there has been a demand for a substance that exhibits a significant growth inhibitory effect on a cancer cell with fewer side effects as a health food and a pharmaceutical composition. It has been found that a hexane extract fraction of a watermelon sprout has an effect of specifically inhibiting the cell growth of the cancer cell and such an effect is primarily caused by phytol and lutein. A processed food and pharmaceutical composition having these substances as main components can exert an anticancer action without causing side effects.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: September 1, 2020
    Assignees: KINKI UNIVERSITY, HAGIHARA FARM PRODUCTION INSTITUTE CO., LTD.
    Inventors: Tomohiro Itoh, Toshiharu Hashizume
  • Publication number: 20200254123
    Abstract: A treatment method is capable of degrading or sterilizing harmful substances or microorganisms of which the degradation, detoxification, or the like is not easy for ozone gas alone. A harmful substance treatment method is one that makes ozone gas act on harmful substances, microorganisms, or the like in an environment humidified using a surfactant solution. The harmful substances include anticancer drugs. As a surfactant to be used, a non-ionic surfactant, an anionic surfactant, a cationic surfactant, or an amphoteric surfactant can be used.
    Type: Application
    Filed: October 10, 2018
    Publication date: August 13, 2020
    Applicants: TAMURA TECO CO., LTD., KINKI UNIVERSITY
    Inventors: Kozo TAMURA, Shunji ISHIWATA, Tomomi INOUE, Takeshi KOTAKE
  • Patent number: 10709767
    Abstract: A medicament effective for prophylactic and/or therapeutic treatment of a peripheral neuropathic pain such as allodynia caused by a treatment with an anticancer agent, which comprises thrombomodulin as an active ingredient.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: July 14, 2020
    Assignees: KINKI UNIVERSITY, ASAHI KASEI PHARMA CORPORATION
    Inventors: Atsufumi Kawabata, Hideaki Suzuki
  • Patent number: 10696878
    Abstract: A fluorene derivative represented by General Formula (1) below. X1—Y—X2??General Formula (1) In the General Formula (1), X1 represents a cyclic carbonate group including a carbonate bond [—O—C(?O)—O—], X2 represents a cyclic carbonate group including a carbonate bond [—O—C(?O)—O—], and Y represents a bivalent group including a 9,9-bisaryl fluorene skeleton.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: June 30, 2020
    Assignees: DEXERIALS CORPORATION, KINKI UNIVERSITY
    Inventors: Hiroto Chiba, Tetsuya Abe, Sungkil Lee, Makiya Ito, Takeshi Endo
  • Patent number: 10675495
    Abstract: A CT value controller includes a storage means, an input means, and a computing means. The storage means stores a function expressing a relative humidity and a CT value regarding a degradation degree of an anticancer agent, an assumed relative humidity, and a CT setting. The input means inputs a measured relative humidity and a measured ozone concentration at a time of degradation treatment of the anticancer agent. The computing means calculates a corrected CT value increment based on a difference between the measured relative humidity and the assumed relative humidity at every input of the relative humidity and the ozone concentration by using the function. The computing means determines a termination of the degradation treatment of the anticancer agent when an integrated CT value of the corrected CT value increments reaches the CT setting.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: June 9, 2020
    Assignees: TAMURA TECO CO., LTD., KINKI UNIVERSITY
    Inventors: Kozo Tamura, Yoshiyuki Fukuda, Shunji Ishiwata, Atsushi Taga
  • Publication number: 20200173999
    Abstract: A method for selecting an individual to be a candidate for administration of an immune checkpoint inhibitor in treatment of a tumor, comprising: (1) a step of collecting a tumor tissue from the individual, (2) a step of determining the extent of B7-H3 expression in the tumor tissue collected in step (1), and (3) a step of selecting the individual as an individual to be a candidate for administration of the immune checkpoint inhibitor if the B7-H3 expression level is considered to be negative, is provided.
    Type: Application
    Filed: December 25, 2017
    Publication date: June 4, 2020
    Applicants: KINKI UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Kimio Yonesaka, Kazuhiko Nakagawa, Kenji Hirotani